News / US / cnbc
AstraZeneca Reports Positive Late-Stage Data for Tozorakimab in COPD Treatment
Health Technology · Pharmaceuticals: Major · cnbc · 2026-09-08
AZN, AZN, SNY, GSK, GILD, SNY, REGN, GSK, IBB
AstraZeneca's experimental COPD drug, tozorakimab, showed significant efficacy in late-stage trials, bolstering the company's multi-billion dollar sales outlook.
What Happened
Clinical Trial Success: AstraZeneca has released full results from two pivotal late-stage trials demonstrating that tozorakimab effectively reduces moderate and severe flare-ups in COPD patients. The drug, which targets the IL-33 protein, showed efficacy across a broad patient population, including both current and former smokers.
Revenue and Market Potential: With peak annual sales projections now exceeding $5 billion, the company views this biologic as a cornerstone for reaching its $80 billion revenue target by 2030. Management emphasizes that the drug addresses a significant unmet need, particularly for patients who do not qualify for currently available biologic therapies.
Mechanism of Action: Unlike previous IL-33 inhibitors that faced development challenges, tozorakimab is designed to block two distinct pathways associated with inflammation and mucus production. This dual-action approach is believed to be the key to its success in treating a wide range of patients, regardless of their eosinophil counts.
Regulatory and Clinical Outlook: The drug is currently under priority review by the FDA, with a potential U.S. launch in early 2027. While clinicians are optimistic about the data, further subgroup analysis is expected to help medical professionals determine the optimal positioning of the drug alongside existing treatments like Dupixent and Nucala.